2024
Cost trends of Metastatic Renal Cell Carcinoma Therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of Metastatic Renal Cell Carcinoma Therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, pkae067. PMID: 39133171, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 1-10. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factors
2023
Managing Chronic Pain in Cancer Survivorship: Communication Challenges and Opportunities as Described by Cancer Survivors
O’Regan A, Fish L, Makarushka C, Somers T, Jones K, Merlin J, Dinan M, Oeffinger K, Check D. Managing Chronic Pain in Cancer Survivorship: Communication Challenges and Opportunities as Described by Cancer Survivors. American Journal Of Hospice And Palliative Medicine® 2023, 41: 78-86. PMID: 36927121, DOI: 10.1177/10499091231164634.Peer-Reviewed Original ResearchPain management experiencesCurative-intent treatmentChronic painCancer survivorsPain managementProvider-initiated communicationChronic pain managementHead/neckCancer survivors' experiencesDecision-making interventionSurvivorship careColorectal cancerClinical managementCancer survivorshipPainPain experienceStage ISurvivorsConvenience sampleSurvivors' experiencesTreatmentFunctional goalsCareThematic approachProviders
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatment